







Barbara Rinehart

RESEARCH REFERENCES

My responsibilities were:

-  Researched specific topic
-  Annotated manuscript
-  Formatted per required style (eg, AMA)
-  Alphabetized

Canada Clinical Trials Group. *J Clin Oncol*. 1998;16:2651-2658.

Munster PN, Hudis CA. Adjuvant therapy for resectable breast cancer. *Hematol/Oncol Clin North Am*. 1999;13:391-413.

Murphy K. Adjuvant Chemotherapy. Available at <http://www.cancerquide.org/adjutant.html>. Accessed 9/14/2001.

Nabholtz JM, Riva Alessandro. Taxane/Anthracycline combinations: setting a new standard in breast cancer. *The Oncologist*. 2001;6(Suppl 3):5-12.

National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. *J Natl Cancer Inst*. 2001;93:979-89.

NCI. National Cancer Institute. Cancer Facts. Available at http://cis.nci.nih.gov/fact5_6.htm. Accessed 9/14/2001.

NCI. National Cancer Institute. CancerNet. Breast Cancer. Available at: http://cancernet.nci.nih.gov/wyntk_public/breast.htm. Accessed 9/14/2001.

NCI. National Cancer Institute. Cancer Facts. Available at http://cis.nci.nih.gov/fact7_20.htm. Accessed 9/14/2001.

Shapiro CL, Recht A. Side effects of adjuvant treatment of breast

cancer. *N Engl J Med*. 2001;344:1997-2008.

Yarbro CH. Principles of Oncology Nursing. In: Holland JF, Baste RC, Morton DL, Frei E III, Kufe DW, Weichselbaum RR (eds). *Cancer Medicine*. 4th ed. Baltimore, MD: Williams & Wilkins. 1997:1347-1401.

Breast Matters References: Alphabetical

ACS. American Cancer Society. What are the key statistics for breast cancer. Available at http://www.../CRI_2_4_1X_What_are_the_keystatistics_for_breast_cancer_5?si=tearea+CR. Accessed 9/18/2001.

Ackland SP. Drug treatment of breast cancer. *Aust Prescr*. 1998;21:15-18.

Bergh J, Jonsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. *Acta Oncologica*. 2001;40:253-281.

BCSC. Breast Cancer Society of Canada. Breast Cancer History. Available at http://bcsc.html/about/about_history_bc.html. Accessed 9/15/2001.

Coombes RC, Bliss JM, Wils J, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus Fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. *J Clin Oncol*. 1998;14:35-45.

FASG. The French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors-5-year follow-up: results of French Adjuvant Study Group 05 randomized trial. *J Clin*

Oncol. 2001;19:602-11. In: Bergh J, Jonsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. *Acta Oncologica*. 2001;40:253-281.

Fisher B, Anderson S, Wickerhan DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. *J Clin Oncol*. 1997;15:1858-1869.

Dowlatshahi K, Fan m, Snider HC, et al. Lymph node micrometastases from breast carcinoma. *Cancer*. 1997;80:1188-97.

Esteva FJ, Hortobagyi GN. Adjuvant systemic therapy for primary breast cancer. *Surg Clin North Am*. 1999;79:1075-1090.

Harris JR, Lippman ME, Veronesi U, et al. Breast Cancer. *N Engl J Med*. 1992;327:473-480.

Jatoi I. The natural history of breast cancer. *Surg Clin North Am*. 1999;79:949-960.

Levine MN, Bramwell VH, Pritchard J, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of